Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Standard of Care, BVY, Gs-1219
HIV-1-Infection
Phase I
Not Yet Recruiting
Study of GS-1219 in Participants With HIV-1
Aug 04, 2025
―
B/F/Taf
HIV-1-Infection
Phase I
Not Yet Recruiting
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
Jun 27, 2025
―
Sacituzumab Govitecan-Hziy (Sg)
Triple Negative Breast Cancer
Phase I/II
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Apr 08, 2025
―
Gs-0151
Rheumatoid Arthritis
Phase I
Recruiting
Study of GS-0151 in Participants With Rheumatoid Arthritis
Mar 24, 2025
―
Obeldesivir
Rsv Infection
Phase II
Terminated
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
Jan 15, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Gilead Sciences (GILD) have in its pipeline
GILD is currently developing the following drugs: Gs-5319, Standard of Care, BVY, Gs-1219, Gs-4321. These drug candidates are in various stages of clinical development as the company works toward FDA approval.